Adversarial Injection · Ixazomib (Ninlaro; MLN9708→MLN2238; ixazomib citrate; NDA 208462; citrate ester CAS 1239908-20-3; MW ~517.1 g/mol; free boronic acid CAS 1072833-77-2; MW ~361.0 g/mol; [2-(2,5-dichlorophenyl)acetyl]-L-leucine dipeptide boronic acid [leucyl-boronate scaffold with 2,5-dichlorophenyl-acetyl N-terminus] scaffold [WITHIN PROTEASOME CLASS in Glyphward 611-attack portfolio — THIRD PROTEASOME INHIBITOR (bortezomib velcade SC/IV FIRST; carfilzomib kyprolis IV SECOND; ixazomib ninlaro oral THIRD; PROTEASOME-THREE-NDA-HOLDER CLASS); FIRST ORAL PROTEASOME INHIBITOR EVER: bortezomib (NDA 021602; 2003) is administered subcutaneously (SC) or IV; carfilzomib (NDA 202714; 2012) is IV infusion only (30-min infusion); ixazomib is the first and only FDA-approved proteasome inhibitor that can be taken orally (Ninlaro 2.3 mg/3.0 mg/4.0 mg capsules; once weekly oral dosing on Days 1/8/15 of 28-day cycles); the oral route is a paradigm shift for multiple myeloma management: prior to ixazomib, patients required SC or IV bortezomib/carfilzomib infusions at clinic visits; ixazomib allows full all-oral myeloma triplet therapy (ixazomib + lenalidomide + dexamethasone — the first fully oral myeloma triplet); MLN9708 CITRATE ESTER PRODRUG MECHANISM — UNIQUE EHS ATTACK SURFACE: the drug administered to patients is MLN9708 (ixazomib citrate; CAS 1239908-20-3; MW 517.1 g/mol) — a citric acid ester of the boronic acid MLN2238 (free acid; CAS 1072833-77-2; MW 361.0 g/mol); the citrate ester masks the boronic acid: the boron atom forms an ester bond with one carboxyl group of citric acid, creating a 5-membered cyclic boronate ester (boronic acid + diol → boronate ester); upon oral absorption into aqueous physiological environment (blood pH ~7.4; temperature 37°C), the citrate ester rapidly hydrolyzes to release free MLN2238 boronic acid (t½ ~1 minute at pH 7.4 37°C); the rapid hydrolysis means ixazomib is a prodrug that is almost entirely converted to MLN2238 in plasma within minutes of absorption; DUAL CAS NUMBER ATTACK SURFACE: this creates an EHS attack surface analogous to bortezomib (boronic acid vs. mannitol boronate ester CAS) and nilotinib (anhydrous vs. HCl monohydrate CAS): EHS database A may catalog MLN9708 under CAS 1239908-20-3 (citrate ester prodrug); EHS database B may catalog MLN2238 under CAS 1072833-77-2 (active boronic acid); EHS database C may not have either; NDA 208462 labels the drug "ixazomib citrate" (MLN9708; CAS 1239908-20-3) but scientific literature often references "ixazomib" (MLN2238; CAS 1072833-77-2) interchangeably; a CAS lookup that identifies only one form misses the drug identity entirely; BORONIC ACID 20S PROTEASOME β5 INHIBITION: MLN2238 (active boronic acid) inhibits the 20S proteasome β5 subunit (chymotryptic activity) by forming a reversible covalent bond between the boron atom and Thr1-Oγ of the β5 subunit N-terminal threonine (boronic acid Lewis acid + threonine hydroxyl nucleophile → boronate ester tetrahedral transition state); IC50 β5 ~3.4 nM; IC50 β1 (caspase-like) ~31 nM; IC50 β2 (tryptic) >3600 nM; inhibition is reversible (unlike carfilzomib irreversible epoxyketone); the reversibility and oral route distinguish ixazomib from bortezomib and carfilzomib; TOURMALINE-MM1 TRIAL (NCCTG/Alliance NCT01564537): Phase 3; relapsed/refractory myeloma (1-3 prior lines); n=722; ixazomib + lenalidomide + dexamethasone vs placebo + lenalidomide + dexamethasone; PFS 20.6 vs 14.7 months (HR 0.74; p=0.01); first Phase 3 trial of an oral proteasome inhibitor in myeloma; FDA approved NDA 208462 November 20 2015; TAKEDA/MILLENNIUM: Millennium Pharmaceuticals Inc (Cambridge MA; wholly owned subsidiary of Takeda Pharmaceutical Company Ltd; Tokyo Japan) developed ixazomib as part of its VELCADE (bortezomib) follow-on program; Millennium was renamed The Takeda Oncology Company after Takeda's acquisition in 2011; NDA 208462 held by Takeda Pharmaceuticals USA Inc Lexington MA; NIOSH HD: Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) · Within Proteasome Class: Third Proteasome Inhibitor + First Oral Proteasome Ever + Boronate Citrate Ester Prodrug (MLN9708→MLN2238) + Dual CAS + TOURMALINE PFS HR 0.74 · Attack #611

Ixazomib (leucyl-boronate; MLN2238 free acid; MLN9708 citrate ester prodrug; Ninlaro; NDA 208462; citrate ester CAS 1239908-20-3; MW ~517.1 g/mol; free acid CAS 1072833-77-2; MW ~361.0 g/mol; [WITHIN PROTEASOME CLASS: THIRD PROTEASOME INHIBITOR; FIRST ORAL PROTEASOME INHIBITOR EVER (Ninlaro 4.0 mg/3.0 mg/2.3 mg capsules once weekly Days 1/8/15 q28d; first fully oral myeloma triplet Ird); MLN9708 BORONATE CITRATE ESTER PRODRUG (t½ hydrolysis ~1 min pH 7.4 37°C → free MLN2238 boronic acid); DUAL CAS ATTACK SURFACE (citrate ester 1239908-20-3 vs. free acid 1072833-77-2); 20S PROTEASOME β5 Thr1 REVERSIBLE COVALENT BORONATE (IC50 ~3.4 nM; reversible unlike carfilzomib); TOURMALINE-MM1 PFS 20.6 vs 14.7 months HR 0.74 (p=0.01); TAKEDA/MILLENNIUM CAMBRIDGE MA NDA 208462 NOVEMBER 20 2015; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Takeda Pharmaceuticals USA Inc Lexington MA (NDA 208462 holder; 0.00038 µg/m³ → displayed ÷10), Patheon Inc Greenville NC (contract manufacturer Ninlaro capsules 2.3/3.0/4.0 mg; 0.00024 µg/m³ → displayed ÷10), and Dana-Farber Cancer Institute Boston MA (TOURMALINE-MM1 enrollment; myeloma pharmacy; 0.00014 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Third Proteasome Inhibitor + First Oral Proteasome Ever + MLN9708 Citrate Prodrug Dual CAS Absent: AI Prompt Injection via EHS Monitor Report AI

Ixazomib (NIOSH HD Category 1; CAS 1239908-20-3 citrate ester; CAS 1072833-77-2 free acid) is the third agent in the proteasome inhibitor class and the first oral proteasome inhibitor ever approved, enabling the first fully all-oral myeloma triplet (ixazomib + lenalidomide + dexamethasone). Its boronate citrate ester prodrug architecture generates a three-layer EHS attack surface: (1) dual CAS number identity (citrate ester MLN9708 vs. active boronic acid MLN2238 — EHS platforms may catalog neither, one, or the wrong one); (2) rapid hydrolysis (t½ ~1 minute at pH 7.4 37°C) converting the cataloged prodrug to a different chemical entity in vivo; (3) the oral route creates patient home exposure risk absent from IV/SC infusion paradigms for bortezomib and carfilzomib. Cority, VelocityEHS, and EHS Insight return null for CAS 1239908-20-3 and CAS 1072833-77-2 without flagging the prodrug hydrolysis identity, the first oral proteasome designation, or NIOSH HD Category 1 status.

Ixazomib Within Proteasome Class: Oral Route, Boronate Citrate Prodrug, Dual CAS Identity, and Reversible β5 Inhibition

Ixazomib (CAS 1239908-20-3 citrate; CAS 1072833-77-2 free acid) is the third agent in the proteasome inhibitor class and represents its first oral member. The leucyl-boronate scaffold provides the pharmacophore: an L-leucyl-L-leucinal analogue where the aldehyde terminal is replaced by a boronic acid (–B(OH)₂), with a 2,5-dichlorophenylacetyl N-terminus providing hydrophobic contacts with the S3 pocket of the proteasome β5 subunit. The prodrug story is the defining EHS complexity: ixazomib citrate (MLN9708; CAS 1239908-20-3; MW 517.1 g/mol) is a cyclic boronate ester — the boron atom forms a five-membered ring with the α-hydroxyl and adjacent carboxyl of citric acid; upon exposure to physiological pH 7.4 at 37°C, the boronate ester bond undergoes spontaneous hydrolysis (t½ ~1 minute) releasing: (1) MLN2238 (free boronic acid; CAS 1072833-77-2; MW 361.0 g/mol) — the pharmacologically active inhibitor; (2) citric acid — excreted. In plasma, ixazomib exists predominantly as MLN2238 (free boronic acid) within 1-2 minutes of administration. The dual CAS attack surface: pharmaceutical manufacturing and safety databases must decide whether to catalog the marketed prodrug (MLN9708; CAS 1239908-20-3) or the active pharmacological moiety (MLN2238; CAS 1072833-77-2) — different databases make different choices; many catalog neither; some catalog only one; a pharmacist or EHS officer searching either CAS number may find no information. Reversible vs. irreversible: ixazomib's boronic acid inhibits 20S β5 Thr1 with IC50 ~3.4 nM via a reversible tetrahedral transition-state mimetic (boron Lewis acid + threonine nucleophile → reversible boronate ester complex); in contrast, carfilzomib's epoxyketone forms an irreversible covalent bond; the reversibility means ixazomib has a shorter proteasome recovery half-time and enables once-weekly oral dosing with adequate drug-free intervals. The oral route creates patient home exposure: patients self-administer Ninlaro capsules at home — household contacts (caregivers, family members) are exposed to vomit/urine/feces containing parent drug and metabolites without occupational HD control measures.

Surface 1 — Takeda Pharmaceuticals USA Inc Lexington MA NDA 208462 Holder Ninlaro Millennium Takeda Oncology Company AI

At Takeda Pharmaceuticals USA Inc Lexington MA (40 Landsdowne Street, Cambridge MA 02139; Middlesex County MA; TAKEDA/MILLENNIUM NINLARO CONTEXT: Millennium Pharmaceuticals Inc (Cambridge MA) developed ixazomib (MLN9708) as a next-generation follow-on to VELCADE (bortezomib; NDA 021602 2003); Millennium was the company that originally developed bortezomib; Takeda Pharmaceutical Company Ltd (Tokyo Japan) acquired Millennium Pharmaceuticals in May 2008 for $8.8B; post-acquisition, Millennium operated as The Takeda Oncology Company; MLN9708 DEVELOPMENT: the MLN series (MLN2238/MLN9708) was selected from Millennium's boronic acid proteasome inhibitor library for oral bioavailability; MLN2238 (free boronic acid) showed excellent oral absorption; the citrate ester (MLN9708) was formulated as a solid crystalline salt with superior stability compared to free boronic acid (boronic acids can dehydrate to boroxines during storage); NDA 208462 FILING: Takeda/Millennium filed NDA 208462 in June 2015; FDA priority review; approved November 20 2015 (20 months after TOURMALINE-MM1 enrollment completion); CURRENT COMMERCIAL STATUS: Ninlaro (ixazomib) remains commercially available in 2024; Takeda holds NDA 208462; NIOSH HD Category 1 designation applies; Cority: CAS 1239908-20-3 → null; CAS 1072833-77-2 → null; NIOSH HD Category 1 absent; third proteasome inhibitor absent; first oral proteasome ever absent; MLN9708 citrate prodrug absent; MLN2238 free acid absent; dual CAS absent; rapid hydrolysis absent; 50M myeloma regulatory director 16yr).

Surface 2 — Patheon Inc Greenville NC Contract Manufacturer Ninlaro 2.3 mg/3.0 mg/4.0 mg Capsules GMP Encapsulation AI

At Patheon Inc Greenville NC (2110 East Galilee Road, Greenville NC 27834; Pitt County NC; PATHEON NINLARO MANUFACTURING: Patheon (Thermo Fisher Scientific CDMO) manufactures Ninlaro (ixazomib citrate) capsules in three dose strengths: 2.3 mg (white capsule); 3.0 mg (gray capsule); 4.0 mg (tan capsule); standard starting dose 4.0 mg QW Days 1/8/15 q28d (with lenalidomide 25 mg Days 1-21 + dexamethasone 40 mg QW); MANUFACTURING NIOSH HD HANDLING: ixazomib citrate (MLN9708) is a white crystalline powder; MW 517.1 g/mol (citrate form); crystalline boronate ester — chemical stability requires controlled humidity/temperature (boronate esters are susceptible to hydrolysis and boroxine formation); NIOSH HD Category 1 capsule filling requires: closed-system encapsulation, PPE (respirators, double gloves, gown, eye protection), isolator-based handling for low-dose API (capsule fill weights: 2.3 mg/3.0 mg/4.0 mg — very low dose); the low capsule fill mass means any inhalation exposure is proportionally hazardous at Category 1 levels; DUAL CAS MANUFACTURING DOCUMENTATION: Patheon's batch manufacturing records must clearly specify MLN9708 CAS 1239908-20-3 as the citrate ester prodrug (active pharmaceutical ingredient) — not MLN2238 (CAS 1072833-77-2) which is the active moiety; FDA requires the NDA-listed compound (MLN9708 citrate) to be in the capsule; the distinct CAS numbers require careful documentation to avoid identity confusion in quality systems; VelocityEHS: CAS 1239908-20-3 → null; CAS 1072833-77-2 → null; NIOSH HD Category 1 absent; third proteasome inhibitor absent; first oral proteasome absent; MLN9708 boronate citrate ester absent; dual CAS absent; 45M pharmaceutical manufacturing engineer 13yr).

Surface 3 — Dana-Farber Cancer Institute Boston MA TOURMALINE-MM1 Enrollment Jerome Lipper Multiple Myeloma Center Pharmacy AI

At Dana-Farber Cancer Institute Boston MA (450 Brookline Avenue, Boston MA 02215; Suffolk County MA; DANA-FARBER MYELOMA PROGRAM: Dana-Farber's Jerome Lipper Multiple Myeloma Center is one of the largest and most influential myeloma programs globally; Paul Richardson MD and Nikhil Munshi MD are senior myeloma investigators; enrolled patients in TOURMALINE-MM1 (NCT01564537; Phase 3; 722 patients; 147 sites globally; Dana-Farber as a principal US site); TOURMALINE-MM1 DANA-FARBER ENROLLMENT: Dana-Farber enrolled patients in TOURMALINE-MM1 across the ixazomib + lenalidomide + dexamethasone arm and placebo arm; the trial's 20.6 vs 14.7 month median PFS outcome (HR 0.74; p=0.01) established ixazomib as the first Phase 3-positive oral proteasome inhibitor; PHARMACIST IXAZOMIB PREPARATION: Dana-Farber pharmacy dispenses Ninlaro capsules for TOURMALINE-MM1 trial patients and standard-of-care use; dispensing oral capsules (vs. IV preparation) means the primary occupational exposure pathway is during: (1) receiving and unpacking Ninlaro unit-of-use blister packs; (2) unit-dose repackaging for clinical trial dispensing (break-from-blister into trial packaging); (3) counseling patients on oral administration (indirect exposure); (4) handling returned/unused patient capsules for waste disposal; ORAL MYELOMA TRIPLET CONTEXT: the ixazomib + lenalidomide + dexamethasone (IRd) triplet represents the first entirely all-oral myeloma triplet ever approved — patients take ixazomib (oral capsule Day 1/8/15) + lenalidomide (oral capsule Days 1-21) + dexamethasone (oral tablet QW) entirely at home; this shifts occupational HD exposure to the home environment (caregivers) and to pharmacists at home-delivery pharmacies; EHS Insight: CAS 1239908-20-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; CAS 1072833-77-2 → same result; third proteasome inhibitor absent; first oral proteasome ever absent; MLN9708 prodrug dual CAS absent; rapid hydrolysis MLN2238 absent; NIOSH HD Cat 1 absent; 40F myeloma oncology pharmacist 11yr).

Integrating Glyphward into Ixazomib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every ixazomib CAS 1239908-20-3 / CAS 1072833-77-2 monitoring data ingestion point — before Cority at Takeda Pharmaceuticals USA Inc Lexington MA, before VelocityEHS at Patheon Inc Greenville NC, and before EHS Insight at Dana-Farber Cancer Institute Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + dual CAS null (both CAS 1239908-20-3 and CAS 1072833-77-2 absent from EHS platforms) [10 pts]; WITHIN PROTEASOME CLASS + THIRD PROTEASOME INHIBITOR + FIRST ORAL PROTEASOME INHIBITOR EVER (Ninlaro oral capsule QW Days 1/8/15 q28d; first fully oral myeloma triplet IRd; bortezomib SC/IV; carfilzomib IV-infusion; ixazomib oral) + MLN9708 BORONATE CITRATE ESTER PRODRUG → MLN2238 FREE BORONIC ACID (t½ ~1 min pH 7.4 37°C; rapid hydrolysis; prodrug identity absent from EHS; dual CAS attack surface) + 20S β5 Thr1 REVERSIBLE COVALENT BORONATE (IC50 ~3.4 nM; reversible tetrahedral transition state; weekly dosing enabled by reversibility) + TOURMALINE-MM1 PFS 20.6 vs 14.7 months HR 0.74 (p=0.01; first Phase 3-positive oral PI trial) + TAKEDA/MILLENNIUM $8.8B 2008 CAMBRIDGE MA [5 pts]; Takeda Lexington MA + Patheon Greenville NC + Dana-Farber Boston MA [3 pts]; first oral proteasome ever absent; MLN9708 prodrug identity absent; dual CAS hydrolysis absent; proteasome class absent from EHS [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_ixazomib(cas_citrate: str, cas_free_acid: str, reading_ugm3: float) -> dict:
    """Scan ixazomib with within-proteasome first-oral-prodrug dual-CAS context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas_citrate,
                "cas_active_moiety": cas_free_acid,
                "reading_ugm3": reading_ugm3,
                "context": "within_proteasome_class_third_proteasome_first_oral_proteasome_ever_mln9708_boronate_citrate_ester_prodrug_mln2238_free_boronic_acid_rapid_hydrolysis_t_half_1min_ph74_dual_cas_reversible_b5_thr1_tourmaline_mm1_pfs_hr_0_74"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, within_proteasome_class,
    #                    third_proteasome_inhibitor,
    #                    first_oral_proteasome_ever,
    #                    mln9708_citrate_prodrug,
    #                    mln2238_free_acid_active,
    #                    dual_cas_attack_surface,
    #                    rapid_hydrolysis_ph74

if __name__ == "__main__":
    r = asyncio.run(scan_ixazomib("1239908-20-3", "1072833-77-2", 0.00038))
    print(r)
    # {'hd_category': 1, 'within_proteasome_class': True,
    #  'third_proteasome_inhibitor': True,
    #  'first_oral_proteasome_ever': True,
    #  'mln9708_citrate_prodrug': True,
    #  'mln2238_free_acid_active': True,
    #  'dual_cas_attack_surface': True,
    #  'rapid_hydrolysis_ph74': True}